One Hippo and many masters: Differential regulation of the Hippo pathway in cancer

Biochemical Society Transactions

Volumn 42, Issue 4, 2014, Pages 816-821

  Romano, David ^a   Matallanas, David ^a   Frederick, Dennie T ^b   Flaherty, Keith T ^b   Kolch, Walter ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cancer; Cross talk; Drug resistance; Hippo mammalian sterile 20 (MST) pathway; Phosphoinositide 3 kinase (PI3K) Akt pathway; Phosphorylation; Protein protein interaction; RAS association domain family 1 isoform A (RASSF1A)

Indexed keywords

MAMMALIAN STERILE 20 LIKE KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PROTEIN KINASE B; UBIQUITIN; UNCLASSIFIED DRUG; HIPPO PROTEIN, HUMAN; PROTEIN BINDING; PROTEIN SERINE THREONINE KINASE; RAS PROTEIN; STK3 PROTEIN, HUMAN;

APOPTOSIS; CONFERENCE PAPER; DNA METHYLATION; DOWN REGULATION; DROSOPHILA MELANOGASTER; ENZYME ACTIVITY; GENE SILENCING; HUMAN; MITOGENESIS; MOLECULAR INTERACTION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; ANIMAL; DRUG EFFECTS; METABOLISM; PHOSPHORYLATION;

ANIMALS; HUMANS; NEOPLASMS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84905858436     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20140030     Document Type: Conference Paper

References (58)

1. Avruch, J., Zhou, D., Fitamant, J., Bardeesy, N., Mou, F. and Barrufet, L.R. (2012) Protein kinases of the Hippo pathway: regulation and substrates. Semin. Cell Dev. Biol. 23, 770-784
2. Pan, D. (2010) The hippo signaling pathway in development and cancer. Dev. Cell 19, 491-505
3. Yu, F.X., Zhao, B., Panupinthu, N., Jewell, J.L., Lian, I., Wang, L.H., Zhao, J., Yuan, H., Tumaneng, K., Li, H. et al. (2012) Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 150, 780-791
4. Zhou, D., Conrad, C., Xia, F., Park, J.S., Payer, B., Yin, Y., Lauwers, G.Y., Thasler, W., Lee, J.T., Avruch, J. and Bardeesy, N. (2009) Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 16, 425-438
5. Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S. et al. (2011) Role of YAP/TAZ in mechanotransduction. Nature 474, 179-183
6. Aragona, M., Panciera, T., Manfrin, A., Giulitti, S., Michielin, F., Elvassore, N., Dupont, S. and Piccolo, S. (2013) A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell 154, 1047-1059
7. O'Neill, E., Rushworth, L., Baccarini, M. and Kolch, W. (2004) Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 306, 2267-2270
8. Matallanas, D., Romano, D., Yee, K., Meissl, K., Kucerova, L., Piazzolla, D., Baccarini, M., Vass, J.K., Kolch, W. and O'Neill, E. (2007) RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol. Cell 27, 962-975
9. Romano, D., Matallanas, D., Weitsman, G., Preisinger, C., Ng, T. and Kolch, W. (2010) Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, Raf-1, and Akt. Cancer Res. 70, 1195-1203
10. Polesello, C., Huelsmann, S., Brown, N.H. and Tapon, N. (2006) The Drosophila RASSF homolog antagonizes the hippo pathway. Curr. Biol. 16, 2459-2465
11. Rauch, J., O'Neill, E., Mack, B., Matthias, C., Munz, M., Kolch, W. and Gires, O. (2010) Heterogeneous nuclear ribonucleoprotein H blocks MST2-mediated apoptosis in cancer cells by regulating A-Raf transcription. Cancer Res. 70, 1679-1688
12. Harvey, K.F., Zhang, X. and Thomas, D. M (2013) The Hippo pathway and human cancer. Nat. Rev. Cancer 13, 246-257
13. O'Neill, E. and Kolch, W. (2005) Taming the Hippo: Raf-1 controls apoptosis by suppressing MST2/Hippo. Cell Cycle 4, 365-367
14. Matallanas, D., Birtwistle, M., Romano, D., Zebisch, A., Rauch, J., von Kriegsheim, A. and Kolch, W (2011) Raf family kinases: old dogs have learned new tricks. Genes Cancer 2, 232-260
15. Agathanggelou, A., Cooper, W.N. and Latif, F. (2005) Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res. 65, 3497-3508
16. Rauch, J., O'Neill, E., Mack, B., Matthias, C., Munz, M., Kolch, W. and Gires, O. (2010) Heterogeneous nuclear ribonucleoprotein H blocks MST2-mediated apoptosis in cancer cells by regulating A-Raf transcription. Cancer Res. 70, 1679-1688
17. Lee, S.J., Lee, M.H., Kim, D.W., Lee, S., Huang, S., Ryu, M.J., Kim, Y.K., Kim, S.J., Hwang, J.H., Oh, S. et al. (2011) Cross-regulation between oncogenic BRAF(V600E) kinase and the MST1 pathway in papillary thyroid carcinoma. PLoS ONE 6, e16180
18. Turajlic, S., Ali, Z., Yousaf, N. and Larkin, J. (2013) Phase I/II RAF kinase inhibitors in cancer therapy. Expert Opin. Invest. Drugs 22, 739-749
19. Zambon, A., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Marais, R. and Springer, C.J. (2012) Small molecule inhibitors of BRAF in clinical trials. Bioorg. Med. Chem. Lett. 22, 789-792
20. Flaherty, K.T., Yasothan, U. and Kirkpatrick, P. (2011) Vemurafenib. Nat. Rev. Drug Discov. 10, 811-812
21. Sullivan, R.J. and Flaherty, K.T. (2013) Resistance to BRAF-targeted therapy in melanoma. Eur. J. Cancer 49, 1297-1304
22. Villanueva, J., Vultur, A. and Herlyn, M. (2011) Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res. 71, 7137-7140
23. Carnero, A., Blanco-Aparicio, C., Renner, O., Link, W. and Leal, J.F. (2008) The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr. Cancer Drug Targets 8, 187-198
24. Shi, Y., Paluch, B.E., Wang, X. and Jiang, X. (2012) PTEN at a glance. J. Cell Sci. 125, 4687-4692
25. O'Neill, A.K., Niederst, M.J. and Newton, A.C. (2012) Suppression of survival signalling pathways by the phosphatase PHLPP. FEBS J. 280, 572-583
26. Warfel, N.A. and Newton, A.C. (2011) Pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP): a new player in cell signaling. J. Biol. Chem. 287, 3610-3616
27. Qiao, M., Wang, Y., Xu, X., Lu, J., Dong, Y., Tao, W., Stein, J., Stein, G.S., Iglehart, J.D., Shi, Q. and Pardee, A.B. (2010) Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis. Mol. Cell 38, 512-523
28. Cassinelli, G., Zuco, V., Gatti, L., Lanzi, C., Zaffaroni, N., Colombo, D. and Perego, P. (2013) Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells. Curr. Med. Chem. 20, 1923-1945
29. Burris, 3rd, H.A. (2013) Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother. Pharmacol. 71, 829-842
30. Downward, J. (2003) Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3, 11-22
31. Cox, A.D. and Der, C.J. (2003) The dark side of Ras: regulation of apoptosis. Oncogene 22, 8999-9006
32. Matallanas, D., Romano, D., Al-Mulla, F., O'Neill, E., Al-Ali, W., Crespo, P., Doyle, B., Nixon, C., Sansom, O., Drosten, M. et al. (2011) Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. Mol. Cell 44, 893-906
33. Navas, C., Hernandez-Porras, I., Schuhmacher, A.J., Sibilia, M., Guerra, C. and Barbacid, M. (2012) EGF receptor signaling is essential for K-Ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 22, 318-330
34. Cao, D., Chen, Y., Tang, Y., Peng, X.C., Dong, H., Li, L.H., Cheng, K., Ge, J. and Liu, J.Y. (2013) Loss of RASSF1A expression in colorectal cancer and its association with K-ras status. Biomed. Res. Int. 2013, 976765
35. Romano, D., Maccario, H., Doherty, C., Quinn, N.P., Kolch, W. and Matallanas, D. (2013) The differential effects of wild-type and mutated K-Ras on MST2 signaling are determined by K-Ras activation kinetics. Mol. Cell. Biol. 33, 1859-1868
36. Castellano, E., Sheridan, C., Thin, M.Z., Nye, E., Spencer-Dene, B., Diefenbacher, M.E., Moore, C., Kumar, M.S., Murillo, M.M., Gronroos, E. et al. (2013) Requirement for interaction of PI3-kinase p110 with RAS in lung tumor maintenance. Cancer Cell 24, 617-630
37. McCubrey, J.A., Steelman, L.S., Chappell, W.H., Abrams, S.L., Franklin, R.A., Montalto, G., Cervello, M., Libra, M., Candido, S., Malaponte, G. et al. (2012) Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 3, 1068-1111
38. McCubrey, J.A., Steelman, L.S., Chappell, W.H., Abrams, S.L., Montalto, G., Cervello, M., Nicoletti, F., Fagone, P., Malaponte, G., Mazzarino, M.C. et al. (2012) Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget 3, 954-987
39. Castellano, E. and Santos, E. (2011) Functional specificity of Ras isoforms: so similar but so different. Genes Cancer 2, 216-231
40. Jeng, H.H., Taylor, L.J. and Bar-Sagi, D. (2012) Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis. Nat. Commun. 3, 1168
41. Young, A., Lou, D. and McCormick, F. (2012) Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov. 3, 112-123
42. Oh, H.J., Lee, K.K., Song, S.J., Jin, M.S., Song, M.S., Lee, J.H., Im, C.R., Lee, J.O., Yonehara, S. and Lim, D.S. (2006) Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res. 66, 2562-2569
43. Praskova, M., Khoklatchev, A., Ortiz-Vega, S. and Avruch, J. (2004) Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras. Biochem. J. 381, 453-462
44. Deng, Y., Pang, A. and Wang, J.H. (2003) Regulation of mammalian STE20-like kinase 2 (MST2) by protein phosphorylation/dephosphorylation and proteolysis. J. Biol. Chem. 278, 11760-11767
45. Glantschnig, H., Rodan, G.A. and Reszka, A.A. (2002) Mapping of MST1 kinase sites of phosphorylation: activation and autophosphorylation. J. Biol. Chem. 277, 42987-42996
46. Guo, C., Zhang, X. and Pfeifer, G.P. (2011) The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2. J. Biol. Chem. 286, 6253-6261
47. Donninger, H., Vos, M.D. and Clark, G.J. (2007) The RASSF1A tumor suppressor. J. Cell Sci. 120, 3163-3172
48. Song, H., Mak, K.K., Topol, L., Yun, K., Hu, J., Garrett, L., Chen, Y., Park, O., Chang, J., Simpson, R.M. et al. (2010) Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc. Natl. Acad. Sci. U.S.A. 107, 1431-1436
49. Avruch, J., Zhou, D., Fitamant, J. and Bardeesy, N. (2010) Mst1/2 signalling to Yap: gatekeeper for liver size and tumour development. Br. J. Cancer 104, 24-32
50. Seidel, C., Schagdarsurengin, U., Blumke, K., Wurl, P., Pfeifer, G.P., Hauptmann, S., Taubert, H. and Dammann, R. (2007) Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol. Carcinog. 46, 865-871
51. Takahashi, Y., Miyoshi, Y., Takahata, C., Irahara, N., Taguchi, T., Tamaki, Y. and Noguchi, S. (2005) Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin. Cancer Res. 11, 1380-1385
52. Lin, X., Cai, F., Li, X., Kong, X., Xu, C., Zuo, X. and Yang, Q. (2013) Prognostic significance of mammalian sterile 20-like kinase 1 in breast cancer. Tumour Biol. 34, 3239-3243
53. Minoo, P., Zlobec, I., Baker, K., Tornillo, L., Terracciano, L., Jass, J.R. and Lugli, A. (2007) Prognostic significance of mammalian sterile20-like kinase 1 in colorectal cancer. Mod. Pathol. 20, 331-338
54. Ho, K.C., Zhou, Z., She, Y.M., Chun, A., Cyr, T.D. and Yang, X. (2013) Itch E3 ubiquitin ligase regulates large tumor suppressor 1 stability. Proc. Natl. Acad. Sci. U.S.A. 108, 4870-4875
55. Salah, Z., Melino, G. and Aqeilan, R.I. (2011) Negative regulation of the Hippo pathway by E3 ubiquitin ligase ITCH is sufficient to promote tumorigenicity. Cancer Res. 71, 2010-2020
56. Yeung, B., Ho, K.C. and Yang, X. (2013) WWP1 E3 ligase targets LATS1 for ubiquitin-mediated degradation in breast cancer cells. PLoS ONE 8, e61027
57. Lignitto, L., Arcella, A., Sepe, M., Rinaldi, L., Delle Donne, R., Gallo, A., Stefan, E., Bachmann, V.A., Oliva, M.A. et al. (2013) Proteolysis of MOB1 by the ubiquitin ligase praja2 attenuates Hippo signalling and supports glioblastoma growth. Nat. Commun. 4, 1822
58. Teraishi, F., Guo, W., Zhang, L., Dong, F., Davis, J.J., Sasazuki, T., Shirasawa, S., Liu, J. and Fang, B. (2006) Activation of sterile20-like kinase 1 in proteasome inhibitor bortezomib-induced apoptosis in oncogenic K-ras-transformed cells. Cancer Res. 66, 6072-6079